Axol Bioscience Ltd. announced that its hiPSC-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.
[Axol Bioscience Ltd (THE SCIENTIST)]
Home Newsletters ESC & iPSC News Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve...
